Biocon | Page 2 | Business Upturn

Latest Articles

Biocon Biologics’ Yesafili gains public funding in Ontario for Retinal Disease Treatment

Corporates · Sep 18, 2025

blank

Top stocks to watch today, September 18: TVS Motor, Biocon, Aurobindo Pharma, Bandhan Bank, Federal Bank and more

Stock Market · Sep 18, 2025

blank

Biocon Biologic secures U.S. FDA approval for Bosaya and Aukelso, Denosumab Biosimilars

Corporates · Sep 17, 2025

blank

Biocon shares jump 3% as company expand diabetes portfolio with USFDA approval of Kirsty

Stock Market · Jul 16, 2025

blank

Top stocks in focus on July 16: Biocon, Dixon Technologies, IndiGo, ICICI Lombard, HDFC Life and more

Stock Market · Jul 16, 2025

blank

Biocon Biologics gets UK marketing authorisation for Vevzuo and Evfraxy

Corporates · Jul 7, 2025

blank

Biocon shares in focus as company reportedly plans to launch QIP to raise up to Rs 4,500 crore

Stock Market · Jun 16, 2025

BSE

Top stocks to watch today, June 3: HCLTech, Mphasis, Britannia Industries, Torrent Power, Biocon and more

Stock Market · Jun 3, 2025

blank

Biocon receives CDSCO approval for its Liraglutide drug in India

Corporates · Jun 2, 2025

blank

Biocon Biologics receives UK MHRA approval for YESINTEK, Biosimilar Ustekinumab

Corporates · May 25, 2025

blank

Biocon subsidiary and Yoshindo expand access to Ustekinumab Biosimilar in Japan

Corporates · May 21, 2025

blank

Biocon share price jumps 4% after its subsidiary receives multiple market access agreements for Yesintek

Stock Market · May 5, 2025

blank

Biocon Biologics secures multiple US market access for Yesintek

Corporates · May 5, 2025

blank

Biocon shares jump 3% as its subsidiary secures US market entry for Yesafili

Stock Market · Apr 15, 2025

blank

Biocon Biologics receives U.S. FDA approval for bevacizumab biosimilar JOBEVNE

Corporates · Apr 10, 2025

Showing 30 of 70 articles